GIP/GLP-1 Coagonist III is under clinical development by Eli Lilly and Co and currently in Phase I for Cardiometabolic Disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback